BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37656352)

  • 1. Comparison of Anti-Trop2 Extracellular Domain Antibodies Generated Against Peptide and Protein Immunogens for Targeting Trop2-Positive Tumour Cells.
    Kamble PR; Kulkarni B; Malaviya A; Bajaj M; Breed AA; Jagtap D; Mahale S; Pathak BR
    Appl Biochem Biotechnol; 2024 Jun; 196(6):3402-3419. PubMed ID: 37656352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma.
    Nakashima K; Shimada H; Ochiai T; Kuboshima M; Kuroiwa N; Okazumi S; Matsubara H; Nomura F; Takiguchi M; Hiwasa T
    Int J Cancer; 2004 Dec; 112(6):1029-35. PubMed ID: 15386348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
    Ahmed Y; Berenguer-Pina JJ; Mahgoub T
    Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
    Liu X; Li J; Deng J; Zhao J; Zhao G; Zhang T; Jiang H; Liang B; Xing D; Wang J
    Front Immunol; 2023; 14():1332489. PubMed ID: 38179054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells.
    Chizari M; Fani-Kheshti S; Taeb J; Farajollahi MM; Mohsenzadegan M
    Recent Pat Anticancer Drug Discov; 2021; 16(1):73-83. PubMed ID: 33176663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.
    Somboonpatarakun C; Phanthaphol N; Suwanchiwasiri K; Ramwarungkura B; Yuti P; Poungvarin N; Thuwajit P; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2024 Mar; 129():111631. PubMed ID: 38359664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TROP2 conjugated hollow gold nanospheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells.
    Liu T; Tian J; Chen Z; Liang Y; Liu J; Liu S; Li H; Zhan J; Yang X
    Nanotechnology; 2014 Aug; 25(34):345103. PubMed ID: 25102337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo.
    Lin H; Zhang H; Wang J; Lu M; Zheng F; Wang C; Tang X; Xu N; Chen R; Zhang D; Zhao P; Zhu J; Mao Y; Feng Z
    Int J Cancer; 2014 Mar; 134(5):1239-49. PubMed ID: 23982827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
    Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.
    Mosolits S; Steinitz M; Harmenberg U; Ruden U; Eriksson E; Mellstedt H; Fagerberg J
    Cancer Immunol Immunother; 2002 Jun; 51(4):209-18. PubMed ID: 12012108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
    Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
    Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ImmunoPET imaging of Trop2 in patients with solid tumours.
    Huang W; Zhang Y; Cao M; Wu Y; Jiao F; Chu Z; Zhou X; Li L; Xu D; Pan X; Guan Y; Huang G; Liu J; Xie F; Wei W
    EMBO Mol Med; 2024 May; 16(5):1143-1161. PubMed ID: 38565806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.
    Caro-Aguilar I; Rodríguez A; Calvo-Calle JM; Guzmán F; De la Vega P; Patarroyo ME; Galinski MR; Moreno A
    Infect Immun; 2002 Jul; 70(7):3479-92. PubMed ID: 12065487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer.
    Shen X; Jin J; Ding Y; Wang P; Wang A; Xiao D; Xue X; Zhu S; Zhang L; Zhu G
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1529-38. PubMed ID: 23842851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope mapping of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave-assisted synthesis of the peptide antigens and ELISA screening.
    Pacini G; Ieronymaki M; Nuti F; Sabatino G; Larregola M; Aharoni R; Papini AM; Rovero P
    J Pept Sci; 2016 Jan; 22(1):52-8. PubMed ID: 26663200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.
    Fagerberg J; Steinitz M; Wigzell H; Askelöf P; Mellstedt H
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4773-7. PubMed ID: 7539133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope mapping of SCLC-cluster-2 MAbs and generation of antibodies directed against new EGP-2 epitopes.
    Helfrich W; Koning PW; The TH; De Leij L
    Int J Cancer Suppl; 1994; 8():64-9. PubMed ID: 7515032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.